Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
Conference Call October 20, 8:45am ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH),…
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
Conference Call October 20, 8:45am ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH),…
Zarminali Pediatrics Welcomes New Chief Technology Officer to Advance Patient-Centric Connected Care Model
CHICAGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Zarminali Pediatrics, the first outpatient…
London School Joins Always Active Uniform Pilot to Combat Childrens Inactivity and Obesity Levels
Wednesday 1 October, 2025 Reception pupils at Harbinger Primary School received free…
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented…
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint…
Global Active Cyber Insurance Leader Coalition Launches in France
With Capacity Provided by Allianz, Active Insurance is Now Available to Businesses…
C2N Announces Major Global Expansion, Adds Six New International Partners
PrecivityAD2â„¢ blood test now available in over seven additional countries with primary…
Successful Completion of First CRS with HIPEC on a 60-year-old Woman with Advanced Peritoneal Carcinomatosis
KOLKATA, India, July 28, 2025 /PRNewswire/ -- In a landmark achievement, a…
